Références

[1] Lundh A, Barbateskovic M, Hróbjartsson A, et al. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. PLOS Medicine 2010;7(10):e1000354.

[2] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109–22. doi:10.1056/NEJMoa0706628 [published Online First: 5 November 2007].

[3] Hwang TJ, Carpenter D, Lauffenburger JC, et al. Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Intern Med 2016;176(12):1826–33. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2565686.

[4] Gerstein HC, McMurray J, Holman RR. Real-world studies no substitute for RCTs in establishing efficacy. The Lancet 2019;393(10168):210–11.

[5] Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. The Lancet 2014;383(9912):156–65.

[6] Tan DSW, Felip E, Castro G de, et al. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. JCO 2024;42(2):192–204. doi:10.1200/JCO.23.00980 [published Online First: 1 December 2023].

[7] Davies J, Martinec M, Delmar P, et al. Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib. J Comp Eff Res 2018;7(9):855–65.

[8] Garon EB, Lu S, Goto Y, et al. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial. JCO 2024;42(2):180–91. doi:10.1200/JCO.23.00910 [published Online First: 3 October 2023].